{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T11:42:24Z","timestamp":1703850144646},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004470","name":"Daewoong","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004470","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dilated cardiomyopathy (DCMP) is characterized by ventricular chamber enlargement and systolic dysfunction which may cause heart failure. Patients with DCMP have overactivation of the renin-angiotensin-aldosterone systems, which can also adversely affect myocardial metabolism in heart failure. The impairment of myocardial metabolism can contribute to the progression of left ventricular remodeling and contractile dysfunction in heart failure. Although angiotensin II receptor blockers (ARBs) have been used to treat patients with DCMP, there has been no direct comparison of the efficacy of these agents. The objective of this study is to compare the effects of olmesartan and valsartan on myocardial metabolism in patients with DCMP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>The OVOID study (a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy) is designed as a non-blinded, open-label, parallel-group, prospective, randomized, controlled, multicenter clinical trial. A total of 40 DCMP patients aged between 20 and 85\u2009years will be randomly allocated into the olmesartan or the valsartan group. <jats:sup>18<\/jats:sup>F-fluoro-2-deoxyglucose (FDG) cardiac positron emission tomography (PET) will be performed at baseline and six months after receiving the study agent. The primary endpoint is myocardial glucose consumption per square meter, measured using <jats:sup>18<\/jats:sup>F-FDG PET 6 months after receiving the study agent.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The purpose of this trial is to compare the efficacy between olmesartan and valsartan in improving myocardial metabolism in DCMP patients. This will be the first randomized comparative study investigating the differential effects of ARBs on heart failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04174456?term=NCT04174456&amp;draw=2&amp;rank=1\">NCT04174456<\/jats:ext-link>. Registered on 18 November 2019<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05970-7","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T07:03:09Z","timestamp":1642230189000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Sua","family":"Jo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeyeon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyungil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Bae","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeonghwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Seop","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Hong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"issue":"25","key":"5970_CR1","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1016\/j.jacc.2016.03.590","volume":"67","author":"AG Japp","year":"2016","unstructured":"Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol. 2016;67(25):2996\u20133010. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.590.","journal-title":"J Am Coll Cardiol."},{"issue":"12 Suppl 1","key":"5970_CR2","first-page":"39","volume":"38","author":"AM Katz","year":"1993","unstructured":"Katz AM. Mechanisms and abnormalities of contractility and relaxation in the failing heart. Cardiologia. 1993;38(12 Suppl 1):39\u201343.","journal-title":"Cardiologia."},{"issue":"5","key":"5970_CR3","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/0735-1097(94)90114-7","volume":"24","author":"EJ Eichhorn","year":"1994","unstructured":"Eichhorn EJ, Hesch CN, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24(5):1310\u201320. https:\/\/doi.org\/10.1016\/0735-1097(94)90114-7.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"5970_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1172\/JCI106978","volume":"51","author":"JK Kjekshus","year":"1972","unstructured":"Kjekshus JK, Mjos OD. Effect of inhibition of lipolysis on myocardial oxygen consumption in the presence of isoproterenol. J Clin Invest. 1972;51(7):1767\u201376. https:\/\/doi.org\/10.1172\/JCI106978.","journal-title":"J Clin Invest"},{"key":"5970_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.yjmcc.2013.07.010","volume":"63","author":"J Mori","year":"2013","unstructured":"Mori J, Zhang L, Oudit GY, Lopaschuk GD. Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure. J Mol Cell Cardiol. 2013;63:98\u2013106. https:\/\/doi.org\/10.1016\/j.yjmcc.2013.07.010.","journal-title":"J Mol Cell Cardiol"},{"issue":"8","key":"5970_CR6","doi-asserted-by":"publisher","first-page":"H1103","DOI":"10.1152\/ajpheart.00636.2012","volume":"304","author":"J Mori","year":"2013","unstructured":"Mori J, Alrob OA, Wagg CS, Harris RA, Lopaschuk GD, Oudit GY. ANG II Causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4. Am J Physiol Heart Circ Physiol. 2013;304(8):H1103\u201313. https:\/\/doi.org\/10.1152\/ajpheart.00636.2012.","journal-title":"Am J Physiol Heart Circ Physiol."},{"issue":"1","key":"5970_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","volume":"14","author":"J Hartupee","year":"2017","unstructured":"Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14(1):30\u20138. https:\/\/doi.org\/10.1038\/nrcardio.2016.163.","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"5970_CR8","doi-asserted-by":"publisher","first-page":"e0189315","DOI":"10.1371\/journal.pone.0189315","volume":"12","author":"R Tripathi","year":"2017","unstructured":"Tripathi R, Sullivan R, Fan TM, et al. Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy. PLoS One. 2017;12(12):e0189315. https:\/\/doi.org\/10.1371\/journal.pone.0189315.","journal-title":"PLoS One"},{"issue":"5","key":"5970_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1113\/expphysiol.2005.030908","volume":"90","author":"JG Burniston","year":"2005","unstructured":"Burniston JG, Saini A, Tan LB, Goldspink DF. Angiotensin II induces apoptosis in vivo in skeletal, as well as cardiac, muscle of the rat. Exp Physiol. 2005;90(5):755\u201361. https:\/\/doi.org\/10.1113\/expphysiol.2005.030908.","journal-title":"Exp Physiol."},{"issue":"3","key":"5970_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.yjmcc.2006.06.004","volume":"41","author":"C Pellieux","year":"2006","unstructured":"Pellieux C, Aasum E, Larsen TS, Montessuit C, Papageorgiou I, Pedrazzini T, et al. Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway. J Mol Cell Cardiol. 2006;41(3):459\u201366. https:\/\/doi.org\/10.1016\/j.yjmcc.2006.06.004.","journal-title":"J Mol Cell Cardiol."},{"issue":"2","key":"5970_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/1389450120666190821152000","volume":"21","author":"KD Singh","year":"2020","unstructured":"Singh KD, Karnik SS. Angiotensin type 1 receptor blockers in heart failure. Current drug targets. 2020;21(2):125\u201331. https:\/\/doi.org\/10.2174\/1389450120666190821152000.","journal-title":"Current drug targets."},{"issue":"11","key":"5970_CR12","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1258\/ebm.2010.010016","volume":"235","author":"V Sukumaran","year":"2010","unstructured":"Sukumaran V, Watanabe K, Veeraveedu PT, Thandavarayan RA, Gurusamy N, Ma M, et al. Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy. Exp Biol Med. 2010;235(11):1338\u201346. https:\/\/doi.org\/10.1258\/ebm.2010.010016.","journal-title":"Exp Biol Med."},{"issue":"5","key":"5970_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1524-6175.2001.01136.x","volume":"3","author":"S Oparil","year":"2001","unstructured":"Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens. 2001;3(5):283\u201391. https:\/\/doi.org\/10.1111\/j.1524-6175.2001.01136.x.","journal-title":"J Clin Hypertens"},{"issue":"1","key":"5970_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00129784-200505010-00006","volume":"5","author":"DH Smith","year":"2005","unstructured":"Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5(1):41\u201350. https:\/\/doi.org\/10.2165\/00129784-200505010-00006.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"5970_CR15","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/00004872-200106001-00004","volume":"19","author":"P Laeis","year":"2001","unstructured":"Laeis P, P\u00fcchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl. 2001;19(1):S21\u201332. https:\/\/doi.org\/10.1097\/00004872-200106001-00004.","journal-title":"J Hypertens Suppl"},{"issue":"9","key":"5970_CR16","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2165\/00003495-200868090-00005","volume":"68","author":"LJ Scott","year":"2008","unstructured":"Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008;68(9):1239\u201372. https:\/\/doi.org\/10.2165\/00003495-200868090-00005.","journal-title":"Drugs"},{"key":"5970_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.curtheres.2013.02.002","volume":"74","author":"T Ono","year":"2013","unstructured":"Ono T, Sanai T, Miyahara Y, Noda R. Olmesartan is more effective than other angiotensin receptor antagonists in reducing proteinuria in patients with chronic kidney disease other than diabetic nephropathy. Curr Ther Res Clin Exp. 2013;74:62\u20137. https:\/\/doi.org\/10.1016\/j.curtheres.2013.02.002.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"23","key":"5970_CR18","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/eurheartj\/ehv727","volume":"37","author":"YM Pinto","year":"2016","unstructured":"Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, B\u00f6hm M, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehv727.","journal-title":"Eur Heart J"},{"issue":"27","key":"5970_CR19","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129\u2013200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128.","journal-title":"Eur Heart J"},{"issue":"6","key":"5970_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Colvin MM, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776\u2013803. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.025.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"5970_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40265-013-0041-3","volume":"73","author":"J Demonceau","year":"2013","unstructured":"Demonceau J, Ruppar T, Kristanto P, et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs. 2013;73(6):545\u201362. https:\/\/doi.org\/10.1007\/s40265-013-0041-3.","journal-title":"Drugs"},{"issue":"5","key":"5970_CR22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s12350-016-0522-3","volume":"23","author":"V Dilsizian","year":"2016","unstructured":"Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Dorbala S, et al. ASNC imaging guidelines\/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol. 2016;23(5):1187\u2013226. https:\/\/doi.org\/10.1007\/s12350-016-0522-3.","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"5970_CR23","doi-asserted-by":"publisher","first-page":"W151","DOI":"10.2214\/AJR.07.2409","volume":"190","author":"G Williams","year":"2008","unstructured":"Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008;190(2):W151\u20136. https:\/\/doi.org\/10.2214\/AJR.07.2409.","journal-title":"AJR Am J Roentgenol"},{"key":"5970_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1\u201339.e14. https:\/\/doi.org\/10.1016\/j.echo.2014.10.003.","journal-title":"J Am Soc Echocardiogr"},{"issue":"Supplement 4","key":"5970_CR25","doi-asserted-by":"publisher","first-page":"25S","DOI":"10.2967\/jnumed.115.157503","volume":"56","author":"AC Dimitriu-Leen","year":"2015","unstructured":"Dimitriu-Leen AC, Scholte AJ, Jacobson AF. 123I-MIBG SPECT for evaluation of patients with heart failure. J Nucl Med. 2015;56(Supplement 4):25S\u201330S. https:\/\/doi.org\/10.2967\/jnumed.115.157503.","journal-title":"J Nucl Med"},{"issue":"4","key":"5970_CR26","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jcmg.2019.01.042","volume":"13","author":"JGE Zelt","year":"2020","unstructured":"Zelt JGE, deKemp RA, Rotstein BH, Nair GM, Narula J, Ahmadi A, et al. Nuclear imaging of the cardiac sympathetic nervous system: a disease-specific interpretation in heart failure. JACC Cardiovasc Imaging. 2020;13(4):1036\u201354. https:\/\/doi.org\/10.1016\/j.jcmg.2019.01.042.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7","key":"5970_CR27","first-page":"1062","volume":"42","author":"I Carri\u00f3","year":"2001","unstructured":"Carri\u00f3 I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42(7):1062\u201376.","journal-title":"J Nucl Med"},{"issue":"1","key":"5970_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s12350-012-9655-1","volume":"20","author":"MI Travin","year":"2013","unstructured":"Travin MI. Cardiac autonomic imaging with SPECT tracers. J Nucl Cardiol. 2013;20(1):128\u201343. https:\/\/doi.org\/10.1007\/s12350-012-9655-1.","journal-title":"J Nucl Cardiol."},{"issue":"2","key":"5970_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/s0735-1097(02)01967-8","volume":"40","author":"VG D\u00e1vila-Rom\u00e1n","year":"2002","unstructured":"D\u00e1vila-Rom\u00e1n VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002;40(2):271\u20137. https:\/\/doi.org\/10.1016\/s0735-1097(02)01967-8.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"5970_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/s0735-1097(99)00499-4","volume":"35","author":"AF van den Heuvel","year":"2000","unstructured":"van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2000;35(1):19\u201328. https:\/\/doi.org\/10.1016\/s0735-1097(99)00499-4.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"5970_CR31","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMra000050","volume":"345","author":"KT Weber","year":"2001","unstructured":"Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345(23):1689\u201397. https:\/\/doi.org\/10.1056\/NEJMra000050.","journal-title":"N Engl J Med"},{"issue":"2","key":"5970_CR32","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1073\/pnas.97.2.931","volume":"97","author":"P Paradis","year":"2000","unstructured":"Paradis P, Dali-Youcef N, Paradis F, et al. Overexpression of angiotensin II type 1 receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci. 2000;97(2):931\u20136. https:\/\/doi.org\/10.1073\/pnas.97.2.931.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"5970_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/cvr\/cvn020","volume":"78","author":"K Rivard","year":"2008","unstructured":"Rivard K, Paradis P, Nemer M, Fiset C. Cardiac-specific overexpression of the human type 1 angiotensin II receptor causes delayed repolarization. Cardiovasc Res. 2008;78(1):53\u201362. https:\/\/doi.org\/10.1093\/cvr\/cvn020.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"5970_CR34","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/cvr\/cvn020","volume":"8","author":"S Mathieu","year":"2018","unstructured":"Mathieu S, El Khoury N, Rivard K, Paradis P, Nemer M, Fiset C. Angiotensin II overstimulation leads to an increased susceptibility to dilated cardiomyopathy and higher mortality in female mice. Sci Rep. 2018 Jan 17;8(1):952. https:\/\/doi.org\/10.1093\/cvr\/cvn020.","journal-title":"Sci Rep."},{"issue":"3","key":"5970_CR35","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","volume":"85","author":"WC Stanley","year":"2005","unstructured":"Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093\u2013129. https:\/\/doi.org\/10.1152\/physrev.00006.2004.","journal-title":"Physiol Rev"},{"issue":"1","key":"5970_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CD, et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207\u201358. https:\/\/doi.org\/10.1152\/physrev.00015.2009.","journal-title":"Physiol Rev"},{"issue":"1","key":"5970_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1161\/01.cir.87.1.59.","volume":"87","author":"H Takaoka","year":"1993","unstructured":"Takaoka H, Takeuchi MT, Odake M. Comparison of hemodynamic determinants for myocardial oxygen consumption under different contractile states in human ventricle. Circulation. 1993;87(1):59\u201369. https:\/\/doi.org\/10.1161\/01.cir.87.1.59.\\.","journal-title":"Circulation"},{"issue":"6","key":"5970_CR38","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","volume":"113","author":"T Doenst","year":"2013","unstructured":"Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res. 2013;113(6):709\u201324. https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.300376.","journal-title":"Circ Res"},{"issue":"23","key":"5970_CR39","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667\u201375. https:\/\/doi.org\/10.1056\/NEJMoa010713.","journal-title":"N Engl J Med"},{"issue":"2","key":"5970_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/ehf2.12249","volume":"5","author":"K Park","year":"2018","unstructured":"Park K, Kim YD, Kim KS, Lee SH, Park TH, Lee SG, et al. The impact of a dose of the angiotensin receptor blocker valsartan on post-myocardial infarction ventricular remodelling. ESC Heart Fail. 2018;5(2):354\u201363. https:\/\/doi.org\/10.1002\/ehf2.12249.","journal-title":"ESC Heart Fail"},{"issue":"4","key":"5970_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40256-016-0165-4","volume":"16","author":"CA D\u00e9zsi","year":"2016","unstructured":"D\u00e9zsi CA. The different therapeutic choices with ARBs. Which one to give? When? Why? Am J Cardiovasc Drugs. 2016;16(4):255\u201366. https:\/\/doi.org\/10.1007\/s40256-016-0165-4.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"5970_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40264-014-0239-7","volume":"38","author":"HMA Abraham","year":"2015","unstructured":"Abraham HMA, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 2015;38(1):33\u201354. https:\/\/doi.org\/10.1007\/s40264-014-0239-7.","journal-title":"Drug Saf"},{"issue":"5","key":"5970_CR43","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","volume":"43","author":"Y Ishiyama","year":"2004","unstructured":"Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43(5):970\u20136. https:\/\/doi.org\/10.1161\/01.HYP.0000124667.34652.1a.","journal-title":"Hypertension"},{"issue":"1","key":"5970_CR44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/01.hyp.33.1.207","volume":"33","author":"WB Strawn","year":"1999","unstructured":"Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension. 1999;33(1):207\u201311. https:\/\/doi.org\/10.1161\/01.hyp.33.1.207.","journal-title":"Hypertension"},{"issue":"3","key":"5970_CR45","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1161\/01.hyp.38.3.665","volume":"38","author":"AJ Ferreira","year":"2001","unstructured":"Ferreira AJ, Santos RAS, Almeida AP. Angiotensin-(1-7): cardioprotective effect in myocardial ischemia\/reperfusion. Hypertension. 2001;38(3):665\u20138. https:\/\/doi.org\/10.1161\/01.hyp.38.3.665.","journal-title":"Hypertension"},{"issue":"17","key":"5970_CR46","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1161\/01.CIR.0000092888.63239.54","volume":"108","author":"DB Averill","year":"2003","unstructured":"Averill DB, Ishiyama Y, Chappell MC, Ferrario CM. Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation. 2003;108(17):2141\u20136. https:\/\/doi.org\/10.1161\/01.CIR.0000092888.63239.54.","journal-title":"Circulation"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05970-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05970-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05970-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T07:10:19Z","timestamp":1642230619000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05970-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5970"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05970-7","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved the Dong-A University Hospital Institutional Review Board (IRB 18-215). Written informed consent will be obtained and documented for all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}